Yaohai-Bio

Yaohai-Bio, established in 2010, is a CRDMO service provider specializing in microbial expression systems. Its business focuses on fields such as "recombinant proteins/peptides, nucleic acid drugs, nanobodies, recombinant novel vaccines, and recombinant plasmids," and is committed to building an open and integrated CRO/CDMO/MAH industry-research service platform. The scope of services covers one-stop CMC services throughout the entire life cycle of pharmaceuticals, including engineered strain construction, cell bank establishment, small-scale process development and optimization, pilot-scale process amplification and production, clinical sample preparation, quality standard establishment, analytical method development and validation, compliant production (GMP), quality management system establishment, and registration submission. Currently, the company has received numerous honors, including National High-tech Enterprise, Jiangsu Private Science and Technology Enterprise, Jiangsu Contract-abiding and Credit-valuing Enterprise, Most Growth-oriented High-tech Enterprise, Jiangsu Engineering Technology Research Center, Taizhou Enterprise Technology Center, Taizhou Science and Technology Giant Enterprise, Taizhou Biopharmaceutical Contract Customized R&D Public Service Platform, one of the Most Growth-oriented CXO Enterprises in the 2022 China Biomedical Industry Value List, and TOP10 Most Potential CGT CDMO Enterprises. The company always adheres to the service philosophy of "dedicated service, co-creating the future" and is committed to "establishing global standards, advancing new drug development, and achieving a healthy life," continuously empowering global new drug creation.